Company intelligence / Profile preview

Arcensus

Rostock, Mecklenburg-Vorpommern, Germanyarcensus-diagnostics.com ↗

Ownership: Private
Development stage: Commercial

Overview

Arcensus provides accredited whole genome and exome sequencing-based diagnostics for rare diseases and unclear symptoms, delivering digital reports that support early diagnosis and personalized treatment strategies. The company holds ISO 15189 accreditation for its bioinformatic services. Clinical results are not drug-related but pertain to diagnostic accuracy and utility.

Therapeutic areas: OtherRare Diseases
Modalities: Diagnostic service (Whole Genome Sequencing)Diagnostic service (Whole Exome Sequencing)Bioinformatics analysisArtificial intelligence-based analysis
Industry: Molecular Diagnostics

Partnerships

Local partners for sample collection/logistics in various countries; specific partner names not listed publicly.

Beyond the preview

Go deeper on Arcensus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arcensus.

Explore the full profile